The World Health Organization (WHO) described the initial results of clinical trials in the United Kingdom (UK), which show that dexamethasone can be life-saving for the treatment of patients in critical condition with COVID-19, as a welcome development.
However, he said an in-depth analysis of the intervention would be conducted before issuing clinical recommendations on how and when to use the drug.
WHO Director-General Dr Tedros Adhanom Ghebreyesus made the announcement on Wednesday.
According to him: “this is welcome news. I congratulate the government of the United Kingdom, the University of Oxford, research groups, hospitals, patients and families who collectively contributed to this life-saving breakthrough.
“WHO is looking forward to learning more about dexamethasone research. This is the first treatment that has been shown to reduce mortality in critically ill patients with COVID-19 who need oxygen or ventilator support.
“There are many ongoing clinical trials of COVID-19, including the solidarity trial initiated by who and partners. It is hoped that more treatments under clinical evaluation will lead to better patient outcomes and save lives.
“While we seek treatment for COVID-19, we must continue our active efforts to prevent as many infections as possible by finding, isolating, testing, and caring for each case; as well as tracking and quarantining each contact.”